Publication

- First & Co-First Author, Corresponding Author

(14) Yim, J.†; Park, J.†; Lee, Y.*; Park, J.*
Tetrazine Bioorthogonal Chemistry: Emerging Strategies for Biomedical Applications
2025, In prepraration (†: equally contributed)

(13) Lee, J.†; Yim, J.†; Kim, S.†; Park, J.*
A Photocaged Click-assembled Proteolysis-Targeting Chimera for Spatiotemporal Targeted Protein Degradation.
2025, In prepraration (†: equally contributed)

(12) Ramu, G.; Kim, S.; Park, J.; Cho, H.; Park, H.; Lee, Y.*; Yim, J.*; Park, J.*
Hetero-Aryl Azides as Photocrosslinking Groups for Target Identification.
2025, Submitted

(11) Kim. Y.S.†; Yim, J.†; Kim, T.; Park, J.*; Kim, J.*; Lee, S.*
Dual HDAC6 and HDAC8 Inhibition Enhances STING-Mediated Innate Immune Response via cell-autonomous and non-cell-autonomous responses.
2025, Submitted (†: equally contributed)

(10) Yim, J.†; Lee, J.†; Kim, S.†; Choi, J.-E.†; Jung, S.; Cho, H.; Park, H.*; Lee, J.*; Park, J.*
Discovery of a KLHL41 Ligand for Muscle Cell Specific Protein Degradation.
2025, Under Review (†: equally contributed)

(9) Park, J.†; Hahm, J.†; Yim, J.†; Lee, H.; Hwang, H. M.; Lee, S.; Park, J.-Y; Arun, V.; Kumar, G. J.; Cho, H.; Park, H.; Lee, M.; Lee, J.; Eom, H.; Song, W. J.; Lee, S.*; Kim, E.*; Park, J.*
Investigation of proteome-tetrazine reactivity for a highly selective tetrazine ligation in live cells.
ACS Cent. Sci. 2025, 11, 878–889. (†: equally contributed) [IF: 13.1] [Selected as a Supplementary Cover article] [Highlighted by "First Reaction" in ACS Cent. Sci.]

(8) Yim, J.; Kim, S.; Lee, H.H.; Chung, J.S.; Park, J.*
Fragment-based approaches to discover ligands for tissue-specific E3 ligases.
Expert Opin. Drug Discov. 2024, 19, 1471–1484. [IF: 6.0]

(7) Yim, J.; Park, J.; Kim, G.; Lee, H.H.; Chung, J.S.; Jo, A.*; Koh, M.*; Park, J.*
Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation.
ChemMedChem 2024, e202400326. [IF: 3.6] [Selected as a Cover article]

(6) Yim, J.; Hwang, Y.S.; Lee, J.-J.; Kim, J.H.; Beak, J.Y.; Jeong J.Y.; Choi, Y.; Jin, B.K.; Park, S.B.*
Inflachromene ameliorates Parkinson’s disease by targeting Nrf2-binding Keap1.
Chem. Sci. 2024, 15, 3588–3595. [IF: 9.989]

(5) Yim, J.; Lee, J.; Yi, S.; Koo, J.Y.; Oh, S.; Park, H.; Kim, S.S.; Bae, M.A.; Park, J.*; Park, S.B.*
Phenotype-based screening rediscovered benzopyran-embedded microtubule inhibitors as anti-neuro inflammatory agents.
Exp. Mol. Med. 2022, 54, 2200–2209. [IF: 12.172]

(4) Yim, J.; Park, S. B.*
Label-free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex.
Front. Chem. 2022, 10, 850638. [IF. 5.221]

(3) Hwang, Y.S.†; Yim, J.†; Song, H.†; Park, S. B.*
Improved Th17 Selectivity of α-Galactosylceramide via Noncovalent Interactions with Diether Moiety.
ACS Med. Chem. Lett. 2019, 10, 720–725. (†: equally contributed) [IF: 3.794]

- Co-Author
(2) Cho, W.†; Won, S.†; Choi, Y.; Yi, S.; Park, J.B.; Park, J.-G.; Kim, C.E.; Narayana, C.; Kim, J.H.; Yim, J.; Choi, Y.I.; Lee, D.-S.*; Park, S.B.*
Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy.
Angew. Chem. Int. Ed. 2023, 62, e202300978. [IF: 16.832]

(1) Shin, Y.-H.†; Jung, K.†; Lee, J.; Lee, H.J.; Yim, J.; Kim, J.; Kim, S.*; Park, S. B.*
Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 Entry.
Angew. Chem. Int. Ed. 2022, 61, e2021115695. [IF: 16.832]